Targeting the Ewing sarcoma family of tumors

July 1, 2011

The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta. Van Meir's research aims to reprogram Ewing sarcoma using a small molecule that will target the Ewing sarcoma family of tumors (ESFT) oncoprotein.

Ewing sarcoma, a type of cancer that forms in the bone or soft tissue, affects primarily young children and adolescents. Though current treatment options have prolonged five-year in patients, many face long-term affects from surgery, chemotherapy and radiation, including risk of second cancers from therapy. For patients whose disease has spread to other organs, there's a lack of effective treatment options. In addition, for some survivors, the disease can recur.

Van Meir and his colleagues propose to reprogram the ESFT cancer stem cells using a small molecule known as KCN1, which targets the oncoprotein found in the of ESFT. Their research will identify a new class of drugs to induce and stop the proliferation of Ewing sarcoma .

"Van Meir's research offers patients the real promise of a cure one day by identifying the root cause of cancer and eradicating the cancer stem cell, which falls in line with the mission of the Foundation" said Samuel Waxman, M.D., the Founder and the Scientific Director of the SWCRF.

"My grandson Max, who, on the eve of his fourth birthday was diagnosed with an extremely rare form of , was the inspiration for The Max Cure Foundation," said Richard Plotkin, vice chairman of The Max Cure Foundation. "As Max bravely endured two years of treatment – which ultimately led to his remission—my family went into action to raise funds for pediatric cancer research. This grant is the first of three collaborative grants we're committed to sponsoring with SWCRF so that other children will not have to experience long, painful and invasive treatments."

Related Stories

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.